<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327443</url>
  </required_header>
  <id_info>
    <org_study_id>1142777</org_study_id>
    <nct_id>NCT01327443</nct_id>
  </id_info>
  <brief_title>Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis of this proposal is that a reduction in hepatic mitochondrial function&#xD;
      is the main pathophysiology behind NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non&#xD;
      alcoholic steatohepatitis). The investigators further hypothesize that lifestyle&#xD;
      modifications through aerobic exercise training without weight loss or diet-induced weight&#xD;
      loss are effective in reducing NAFLD parameters by improving hepatic mitochondrial content&#xD;
      and function in human subjects.&#xD;
&#xD;
      The investigators propose a randomized, controlled human clinical trial to compare the&#xD;
      effects of aerobic exercise training (without weight loss) versus diet-induced weight loss&#xD;
      (without exercise) in individuals who have NAFLD or liver biopsy-confirmed NASH&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis). The investigators further&#xD;
      hypothesize that lifestyle modifications through aerobic exercise training without weight&#xD;
      loss or diet-induced weight loss are effective in reducing NAFLD parameters by improving&#xD;
      hepatic mitochondrial content and function in human subjects.&#xD;
&#xD;
      The investigators propose a randomized, controlled human clinical trial to compare the&#xD;
      effects of aerobic exercise training (without weight loss) versus diet-induced weight loss&#xD;
      (without exercise) in individuals who have NAFLD or liver biopsy-confirmed NASH&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NASH ( Non alcoholic steatohepatitis score) on liver biopsy</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver Function Tests</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>ALT/AST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DXA Scan</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonographical changes in liver echotexture</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Weight loss</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10% weight loss in 24 weeks time period through nutritional counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise without weight loss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 weeks under direct supervision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No change in usual exercise levels or food intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight loss</intervention_name>
    <description>Nutritional counseling</description>
    <arm_group_label>Weight loss</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Under direct supervision</description>
    <arm_group_label>Exercise without weight loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sedentary individual between&#xD;
&#xD;
          -  age group 18-60 years old&#xD;
&#xD;
          -  elevated Liver Function Tests (LFT's) with fatty liver on ultrasound and biopsy proven&#xD;
             NASH&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant history of alcohol consumption &gt; 20 gm/day (&gt; 2 drinks / day)&#xD;
&#xD;
          -  evidence of other causes of hepatitis including positive screening B &amp; C, autoimmune&#xD;
             hepatitis, hemochromatosis, celiac disease, Wilson's disease, alpha 1 antitrypsin&#xD;
             deficiency or medication-induced hepatitis&#xD;
&#xD;
          -  Subjects with planned exercise &gt; 30-60 minutes per week&#xD;
&#xD;
          -  BMI &lt; 25 or &gt; 44 kg/m2&#xD;
&#xD;
          -  clinical or biochemical evidence of decompensated liver disease, advanced cardiac or&#xD;
             renal disease&#xD;
&#xD;
          -  changes in last 3 months the dose of oral hypoglycemic medication and statin,&#xD;
&#xD;
          -  positive stress test&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  demented individuals who cannot give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamal Ibdah, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Jamal Ibdah</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Exercise</keyword>
  <keyword>NAS scores</keyword>
  <keyword>Mitochondrial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

